Publications and Presentations

Category:

Merrill et al - Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial
Click to View
Shah et al - Post-Hoc Analysis of Suprachoroidal Injection Experience for Non-Infectious Uveitis
Click to View
Goldstein et al - Uveitic Macular Edema: OCT Anatomic and Temporal Biomarkers
Click to View
Kuhrana et al - Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)
Click to View
Henry et al - Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)
Click to View
Suhler et al - Post Hoc Analysis of Suprachoroidal CLS-TA versus Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function
Click to view
Grewal et al - OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
Click to View
Nguyen - Results from the Phase 3 PEACHTREE Clinical Trial Systemic Therapy and the Efficacy of CLS-TA: a Post-Hoc Analysis
Click to View
Merrill - Results from the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post-Hoc Analysis
Click to View
Henry et al - Results from the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post-Hoc Analysis
Click to View
Nguyen - Variations in Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA) Results from the Phase 3 PEACHTREE Clinical Trial for Uveitic Macular Edema
Click to View
Reddy et al - Results from the Phase 3 PEACHTREE Clinical Trial: Systemic Therapy and the Efficacy of CLS-TA, a Post-Hoc Analysis
Click to View
Yeh et al - Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3, Randomized Trial
Click to View
Singer - IOP Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA): Results from the Phase 3 PEACHTREE Clinical Trial for Uveitis
Click to View
Yeh - Front-line Local Therapies for Uveitis: From Clinical Trials to Practice
Click to View
Stephen Yeh - Suprachoroidal Injection of Triamcinolone Acetonide, CLS-TA, for Macular Edema Due to Noninjectious Uveitis: A Randomized, Phase 2 Study (DOGWOOD)
Click to View
Levison - A Subgroup Analysis of Subjects Diagnosed with Anterior Uveitis from the Phase 3 PEACHTREE Clinical Trial
Click to view
Yeh - Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA) and Intraocular Pressure: Results from the Phase 3 PEACHTREE Clinical Trial for Uveitis
Click to view
Merrill – Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA) and Intraocular Pressure: Results from the Phase 3 PEACHTREE Clinical Trial for Uveitis
Click to view
Sharma - Suprachoroidal CLS-TA Maintains Efficacy Outcomes Through 48-weeks in Uveitic Macular Edema subjects: Results of the MAGNOLIA Phase 3 Extension Study
Click to view
Neumann – Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study
Click to view
Henry - Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study
Click to view
Merrill - Suprachoroidally Injected CLS-TA in Uveitis Maintains Efficacy Outcomes Through 48 Weeks: Results of the MAGNOLIA Phase 3 Extension Study
Click to view
Henry - Treatment response analysis of visual acuity and central subfield retinal thickness following suprachoroidal CLS-TA
Click to view
Suhler - Suprachoroidal Administration of Triamcinolone Acetonide (CLS-TA) for the treatment of Macular Edema in Noninfectious Uveitis: Pooled Results of Three Clinical Trials
Click to view
Yeh - Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study
Click to view
Hariprasad - Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of Macular Edema in a Majority of Patients
Click to view
Henry - Suprachoroidal Delivery of CLS-TA for Uveitic Macular Edema: Results of the Phase 3 PEACHTREE Trial
Click to view
Merrill - Suprachoroidal CLS-TA Maintains Efficacy Outcomes Through 48-weeks in Uveitic Macular Edema subjects: Results of the MAGNOLIA Phase 3 Extension Study
Click to view
Yeh, S. - Suprachoroidally Injected CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveities Results of the Phase 3 PEACHTREE Study
Click to view
Burke, B. - Targeted delivery of Triamcinolone Acetonide and CLS011A To the posterior ocular tissues via Suprachoroidal administration
Click to view
Shah, M. - Development and clinical experience with Suprachoroidal injection of Triamcinolone acetonide (CLS-TA) as a local treatment for noninfectious uveitis
Click to view
Hariprasad, S. - Patient Safety Data Across Clinical Trials Using Suprachoroidal Injection of Triamcinolone Acetonide
Click to view
Wang, R. - The potential for treatment of noninfectious uveitis using a suprachoroidal approach
Click to view
Goldstein D, Do D, Noronha G, Kissner J, Srivastava S, Nguyen Q. - Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis
Click to view
Yeh S. - Suprachoroidal Administration of Triamcinolone Acetonide: Results of a Phase 2 Study of Patients with Noninfectious Uveitis
Click to view
Do D. - Clinical Trial Results From Patients With Macular Edema Due to Noninfectious Uveitis Treated With 4.0 mg of Triamcinolone Acetonide Using a Suprachoroidal Injection
Click to view
Debra A. Goldstein - Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis
Click to View
Hariprasad S. - Suprachoroidal Administration of Triamcinolone Acetonide: Combined Results of Phase 1/2 and Phase 2 Clinical Studies
Click to view
Gilger B, Abarca E, Salmon J, Patel S. - Treatment of Acute Posterior Uveitis by Injection of Triamcinolone Acetonide into the Suprachoroidal Space Using Microneedles.
Click to view

As a courtesy to our stakeholders, Clearside Biomedical, Inc. lists posters and presentations delivered on, or related to our programs at various medical meetings and in various publications. Some of these materials may be authored by individuals outside the Company with or without funding from Clearside. Please note that the studies, data, opinions, and other disclosures made by these individuals may not fully reflect the status of the Clearside programs. Clearside Biomedical does not by its reference above or distribution necessarily imply its endorsement of or concurrence with such information, conclusions, or recommendations.